• Janssen's lead coronavirus vaccine shows preclinical promise pharmatimes
    September 07, 2020
    Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters when challenged with SARS-CoV-2, the virus that causes COVID-19 in people.
  • Janssen to Discontinue Pimodivir Influenza Development Program americanpharmaceuticalreview
    September 04, 2020
    The Janssen Pharmaceutical Companies of Johnson & Johnson has made a strategic decision to discontinue the development of pimodivir, an investigational antiviral treatment for influenza A infection.
PharmaSources Customer Service